54-Year-Old Man is Found to Have a Mass in the Right Kidney

July 2nd 2025

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Daniella Natanov;Sharon Koehler

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Russ Conroy

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Related Content

July 2nd 2025

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Benjamin J. Golas, MD

June 30th 2025

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Daniella Natanov;Sharon Koehler

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

Russ Conroy